A phase II clinical trial for evaluating the efficacy and safety of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin in inhibition of platelet aggregation

Objective:To evaluate the efficacy and safety of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin in inhibition of platelet aggregation in Chinese cardiovascular patients.Methods: We enrolled 223 cardiovascular patients with high platelet aggregation rate who needed the treatment of aspirin.The patients were randomly divided into 2 groups and treated with either oral doses of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablets(contain 162 mg aspirin) or aspirin tablets(150 mg) daily for 6 weeks.Platelet aggregation and urine 11-dTXB2 concentration were measured before and 6 weeks after administration.Results: The platelet aggregation in both groups was significantly inhibited 6 weeks after administration.There was no significant difference in inhibition of platelet aggregation between two groups-(20.28±22.45)% vs-(21.57±23.67)%.The incidence of adverse effects of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablet was lower than those of aspirin tablet.Conclusion: The inhibitive effect of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablet on platelet aggregation is similar to,but its adverse effect is lower than that of aspirin tablet.